CROI 12 (Retrovirus) 2005

Paediatric reports from 12th Conference on Retrovirus and Opportunistic Infections (CROI)

Once-daily lopinavir/ritonavir for children may offer advantages

Lopinavir/ritonavir for young infants

Paediatric dose finding atazanavir and atazanavir/ritonavir

Switching d4T to tenofovir and protease inhibitor to efavirenz

12th Conference on Retrovirus and Opportunistic Infections, 22-25 February, Boston, 2005

Developments in nevirapine use in MTCT reduction

Mashi study – late breakers on breastfeeding

Maternal health and infant mortality

Paediatric care in lower income settings

Tenofovir not linked to bone toxicity in children followed for one year

Gut memory CD4 T cells implicated in a central role for HIV disease pathology: dramatic impact prior to seroconversion

Case of multi-drug resistant (MDR) rapid progressor

Case report of antibody reversion and negative viral load four-years after treatment discontinuation

24-week efficacy of TMC114 in PI-experienced patients

Maturation inhibitor shows anti-HIV activity in single dose pilot study

New antiretrovirals at 12th CROI

Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age

Omega-3 supplement effective to reduce triglycerides

Entecavir is effective against 3TC-resistant hepatitis B

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

Tenofovir is non-inferior to adefovir for the treatment of hepatitis B in HBV-HIV co-infected patients